ATE283700T1 - Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges - Google Patents

Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges

Info

Publication number
ATE283700T1
ATE283700T1 AT00935413T AT00935413T ATE283700T1 AT E283700 T1 ATE283700 T1 AT E283700T1 AT 00935413 T AT00935413 T AT 00935413T AT 00935413 T AT00935413 T AT 00935413T AT E283700 T1 ATE283700 T1 AT E283700T1
Authority
AT
Austria
Prior art keywords
signal transmission
therapeutic use
pathway inhibitor
transmission pathway
hedgehog signal
Prior art date
Application number
AT00935413T
Other languages
English (en)
Inventor
Jonathan Robert Lamb
Gerard Francis Hoyne
Margaret Jane Dallman
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE283700(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9913350.6A external-priority patent/GB9913350D0/en
Priority claimed from GBGB9921953.7A external-priority patent/GB9921953D0/en
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Application granted granted Critical
Publication of ATE283700T1 publication Critical patent/ATE283700T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00935413T 1999-06-08 2000-06-05 Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges ATE283700T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9913350.6A GB9913350D0 (en) 1999-06-08 1999-06-08 Therapeutic use
GBGB9921953.7A GB9921953D0 (en) 1999-09-16 1999-09-16 Therapeutic use
PCT/GB2000/002191 WO2000074706A1 (en) 1999-06-08 2000-06-05 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway

Publications (1)

Publication Number Publication Date
ATE283700T1 true ATE283700T1 (de) 2004-12-15

Family

ID=26315650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935413T ATE283700T1 (de) 1999-06-08 2000-06-05 Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges

Country Status (10)

Country Link
US (1) US20020192216A1 (de)
EP (1) EP1183040B1 (de)
JP (1) JP2003501395A (de)
AT (1) ATE283700T1 (de)
AU (1) AU780358B2 (de)
CA (1) CA2376210A1 (de)
DE (1) DE60016402T2 (de)
ES (1) ES2233383T3 (de)
GB (1) GB0013674D0 (de)
WO (1) WO2000074706A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280736C (en) 1997-02-10 2012-05-29 The President And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60028411T2 (de) 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
IL148972A0 (en) * 1999-10-14 2002-11-10 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CA2392958A1 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CA2412215A1 (en) * 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
AU2002247847A1 (en) * 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
EP1549144A4 (de) * 2002-10-04 2010-01-06 Univ California Verfahren zur behandlung von krebs durch hemmung der wnt-signalleitung
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2005032578A1 (en) * 2003-10-06 2005-04-14 Monash University Therapeutic method
WO2005097207A2 (en) 2004-03-26 2005-10-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
WO2005116236A2 (en) * 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
EP1758926A4 (de) 2004-05-21 2008-04-16 Univ California Verfahren zur behandlung und diagnose von krebs mit wnt inhibitory factor-1 (wif-1)
US8257438B2 (en) * 2005-04-12 2012-09-04 Warsaw Orthopedic, Inc. Methods and devices for preserving motion in an articulating prosthetic disc
WO2007033063A2 (en) * 2005-09-12 2007-03-22 The Board Of Regents Of The University Of Texas System Regulation of the hedgehog signaling pathway and uses thereof
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
EP2066320A1 (de) * 2006-09-27 2009-06-10 Irm, Llc Verfahren und zusammensetzungen zur behandlung von lymphom und myelom
US8536168B2 (en) * 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
GB0707349D0 (en) * 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for accelerating wound healing
WO2009132032A2 (en) * 2008-04-21 2009-10-29 President And Fellows Of Harvard College Sonic hedgehog modulators
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2177208A1 (de) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Pharmazeutische topische Zusammensetzungen
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
DE102010052941A1 (de) * 2010-11-18 2012-05-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutisches Protein
CA2853187A1 (en) * 2011-10-28 2013-05-02 Paranta Biosciences Limited A method of treating mucus hypersecretion
GB201204201D0 (en) * 2012-03-09 2012-04-25 Ucl Business Plc Erythropoiesis
GB201204645D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Treatment of disease
US20150225476A1 (en) * 2012-09-21 2015-08-13 Agency For Science, Technology And Research Method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway
JP5804389B2 (ja) * 2013-01-11 2015-11-04 国立大学法人東北大学 運動に応答して筋肉細胞において発現変動するタンパク質及びそれらの受容体、それらをコードする遺伝子、並びにそれらを用いたスクリーニング方法
US9695178B2 (en) 2013-01-15 2017-07-04 Suzhou Kintor Pharmaceuticals, Inc. 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
CA3029086C (en) 2016-07-04 2021-02-16 Suzhou Kintor Pharmaceuticals, Inc. Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
CN118311175B (zh) * 2024-05-06 2025-12-12 四川新绿色药业科技发展有限公司 一种刺猬皮药材、饮片、标准汤剂及其配方颗粒hplc特征图谱的构建方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196192A (en) * 1988-05-31 1993-03-23 Biotechnology Australia Pty. Ltd. Actions of hormones
IL128999A0 (en) * 1996-09-20 2000-02-17 Harvard College Hedgehog interacting proteins and uses related thereto
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
WO1999063052A2 (en) * 1998-06-03 1999-12-09 The President And Fellows Of Harvard College Bigenic mouse models and assays to identify proliferation and differentiation regulators
JP2002524528A (ja) * 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
DE69942063D1 (de) * 1998-09-11 2010-04-08 Curis Inc Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
DE69939327D1 (de) * 1998-11-02 2008-09-25 Curis Inc Funktionelle antagonisten von hedgehog-aktivität
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2243259T3 (es) * 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
US6743613B2 (en) * 1999-04-23 2004-06-01 Human Genome Sciences, Inc. Lysyl-oxidase HOHEC84 polynucleotides

Also Published As

Publication number Publication date
AU780358B2 (en) 2005-03-17
US20020192216A1 (en) 2002-12-19
JP2003501395A (ja) 2003-01-14
WO2000074706A1 (en) 2000-12-14
EP1183040B1 (de) 2004-12-01
GB0013674D0 (en) 2000-07-26
EP1183040A1 (de) 2002-03-06
DE60016402D1 (de) 2005-01-05
ES2233383T3 (es) 2005-06-16
AU5095500A (en) 2000-12-28
CA2376210A1 (en) 2000-12-14
DE60016402T2 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
DE60016402D1 (de) Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
PT1487541E (pt) Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
GB0002336D0 (en) Medicaments
IN2005KO00312A (de)
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
PT866870E (pt) Proteinas de fusao factor tecidual-dominio de kunitz como inibidores do factor viia
DK1124566T3 (da) Ikke-fermenteret osmotisk laxativ til behandling og forebyggelse af colorectale cancere
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
PT1150704E (pt) Melagatran para o tratamento da inflamacao
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
SE9802209D0 (sv) Novel compounds
AU9067198A (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties